ArticleBMC neurology2022
Neurocognitive screening in patients following SARS-CoV-2 infection: tools for triage.
Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Cognitive outcomes and psychological symptoms in an Italian cohort with post-acute COVID-19 condition (PACC).Heliyon · 2024Article
- Long COVID Is Not a Functional Neurologic Disorder.Journal of personalized medicine · 2024Review
- Objective and subjective cognitive status after intensive care unit treatment for COVID-19.Brain, behavior, & immunity - health · 2024Article
- Molecular cross-talk between long COVID-19 and Alzheimer's disease.GeroScience · 2024Review
- Cognitive function and quantitative electroencephalogram analysis in subjects recovered from COVID-19 infection.BMC neurology · 2024Article
- "Brain Fog" After COVID-19 Infection: How the Field of Neuropsychology Can Help Clear the Air.Advances in experimental medicine and biology · 2024Article
- Changes in Reaction Time, Balance and Neuroplasticity after Exercise with a Face Mask in Male Adults with Mild COVID-19 Symptoms.Healthcare (Basel, Switzerland) · 2023Article
- The functional and structural changes in the hippocampus of COVID-19 patients.Acta neurologica Belgica · 2023Review
- Associations of subjective and objective cognitive functioning after COVID-19: A six-month follow-up of ICU, ward, and home-isolated patients.Brain, behavior, & immunity - health · 2023Article
- Relationship between Reaction Times and Post-COVID-19 Symptoms Assessed by a Web-Based Visual Detection Task.Healthcare (Basel, Switzerland) · 2023Article
- Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19.Brain, behavior, & immunity - health · 2022Article
Corrections and comments
- Update of
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive complaints are common in patients recovering from Coronavirus Disease 2019 (COVID-19), yet their etiology is often unclear. We assess factors that contribute to cognitive impairment in ambulatory versus hospitalized patients during the sub-acute stage of recovery.
methodsIn this cross-sectional study, participants were prospectively recruited from a hospital-wide registry. All patients tested positive for SARS-CoV-2 infection using a real-time reverse transcriptase polymerase-chain-reaction assay. Patients ≤ 18 years-of-age and those with a pre-existing major neurocognitive disorder were excluded. Participants completed an extensive neuropsychological questionnaire and a computerized cognitive screen via remote telemedicine platform. Rates of subjective and objective neuropsychological impairment were compared between the ambulatory and hospitalized groups. Factors associated with impairment were explored separately within each group.
resultsA total of 102 patients (76 ambulatory, 26 hospitalized) completed the symptom inventory and neurocognitive tests 24 ± 22 days following laboratory confirmation of SARS-CoV-2 infection. Hospitalized and ambulatory patients self-reported high rates of cognitive impairment (27-40%), without differences between the groups. However, hospitalized patients showed higher rates of objective impairment in visual memory (30% vs. 4%; p = 0.001) and psychomotor speed (41% vs. 15%; p = 0.008). Objective cognitive test performance was associated with anxiety, depression, fatigue, and pain in the ambulatory but not the hospitalized group.
conclusionsFocal cognitive deficits are more common in hospitalized than ambulatory patients. Cognitive performance is associated with neuropsychiatric symptoms in ambulatory but not hospitalized patients. Objective neurocognitive measures can provide essential information to inform neurologic triage and should be included as endpoints in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.